Chip stocks fall with Nvidia after data center rev disappointment
Investing.com - Stifel has reiterated its Buy rating and $52.00 price target on Dianthus Therapeutics (NASDAQ:DNTH) ahead of important clinical data expected in September. The stock, currently trading at $20.06, has shown strong momentum with a nearly 10% gain over the past week. According to InvestingPro data, analyst targets for DNTH range from $34 to $84, suggesting significant upside potential.
The upcoming Phase 2 data for DNTH103 in Myasthenia Gravis (MG) will represent the first clinical readout for the company and the first C1s antibody readout in this autoimmune condition, according to Stifel’s research note.
Stifel views this as a binary event that could significantly impact DNTH’s valuation, suggesting shares could trade between $30-50 if efficacy proves comparable to C5 inhibitors, while failure might see shares fall toward cash value of $6-10.
The research firm highlights DNTH103’s potential advantages, including a possible differentiated label without a boxed warning and convenient autoinjector administration, which could position it as a preferred complement inhibitor in the growing MG market.
Beyond Myasthenia Gravis, Stifel notes the readout has broader implications for DNTH103 across other indications, including ongoing studies in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN).
In other recent news, Dianthus Therapeutics has completed patient enrollment for its Phase 2 MaGic trial, evaluating the efficacy of DNTH103 in individuals with generalized Myasthenia Gravis. This trial, which included 65 participants, aims to assess the safety and tolerability of DNTH103, with results expected in September 2025. In addition, Stifel has reiterated a buy rating and a $52.00 price target on Dianthus Therapeutics, reflecting confidence in the company’s lead drug candidate, DNTH103, and its potential impact on autoimmune neuromuscular conditions. William Blair has also initiated coverage with an Outperform rating and set a fair value of $47.57 per share. Furthermore, Dianthus Therapeutics announced the appointment of Dr. Simon Read to its Board of Directors, bringing over 30 years of industry experience. Dr. Read praised the company’s progress with DNTH103 and expressed enthusiasm for upcoming trial results. The company continues to focus on developing DNTH103 for various autoimmune conditions, with ongoing trials in Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy. These developments signal a busy period for Dianthus Therapeutics as they advance their pipeline and strengthen their leadership team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.